BIOMARKER TO PREDICT TARGET DRUG EFFICACY FOR HEPATOCELLULAR CARCINOMA AND ITS USE

摘要

The present invention relates to a biomarker which can assort patients adapting to sorafenib and not adapting the sorafenib with high discrimination capacity or a combination of the marker and a use thereof. The marker according to the present invention can simply decide whether adapting the sorafenib or not by noninvasive tests using blood, so the present invention can reduce drug side effects because of being capable administrating individually tailored drug and can reduce cost.